Maternal antibody responses to the 52-kd SSA/Ro p200 peptide and the development of fetal conduction defects

Arthritis and Rheumatism

Volumn 52, Issue 10, 2005, Pages 3079-3086

  Clancy, Robert M ^a   Buyon, Jill P ^a   Ikeda, Keigo ^b   Nozawa, Kazuhisa ^b   Argyle, Dionne A ^a   Friedman, Deborah M ^c   Chan, Edward K L ^b  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c SAINT BARNABAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; MATERNAL ANTIBODY; RO ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CARDIOVASCULAR RISK; CONGENITAL HEART BLOCK; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FETUS; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OPTICAL DENSITY; PR INTERVAL; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, ANTINUCLEAR; APOPTOSIS; EPITOPES; FEMALE; FETAL DISEASES; HEART BLOCK; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYOCYTES, CARDIAC; PEPTIDE FRAGMENTS; PREGNANCY; REGISTRIES; RIBONUCLEOPROTEINS; RISK FACTORS;

EID: 26844446018     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21289     Document Type: Article

References (31)

1. Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001;44:1832-5.
2. Gordon P, Rosenthal E, Simpson JM, Sharland G, Brucato A, Franceschini F, et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol 2004;31:2480-7.
3. Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the Research Registry for Neonatal Lupus. Arthritis Rheum 1999;42:2335-45.
4. Buyon JP, Clancy RM. Neonatal lupus: basic research and clinical perspectives. Rheum Dis Clin North Am 2005;31:299-313.
5. Buyon JP, Slade SG, Reveille JD, Hamel JC, Chan EK. Autoantibody responses to the "native" 52-kDa SS-A/Ro protein in neonatal lupus syndromes, systemic lupus erythematosus, and Sjögren's syndrome. J Immunol 1994;152:3675-84.
6. Julkunen H, Kurki P, Kaaja R, Heikkila R, Immonen I, Chan EK, et al. Isolated congenital heart block: long-term outcome of mothers and characterization of the immune response to SS-A/Ro and to SS-B/La. Arthritis Rheum 1993;36:1588-98.
7. Salomonsson S, Dorner T, Theander E, Bremme K, Larsson P, Wahren-Herlenius M. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 2002;46:1233-41.
8. Salomonsson S, Sonesson SE, Ottosson L, Muhallab S, Olsson T, Sunnerhagen M, et al. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 2005;201:11-7.
9. Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998;31:1658-66.
10. Tseng CE, Caldwell K, Feit S, Chan EK, Buyon JP. Subclass distribution of maternal and neonatal anti-Ro(SSA) and La(SSB) antibodies in congenital heart block. J Rheumatol 1996;23:925-32.
11. Tseng CE, Chan EK, Miranda E, Gross M, Di Donato F, Buyon JP. The 52-kd protein as a target of intermolecular spreading of the immune response to components of the SS-A/Ro-SS-B/La complex. Arthritis Rheum 1997;40:936-44.
12. Glickstein JS, Buyon J, Friedman D. Pulsed Doppler echocardiographic assessment of the fetal PR interval. Am J Cardiol 2000; 86:236-9.
13. Glickstein J, Buyon J, Kim M, Friedman D, and the PRIDE investigators. The fetal Doppler mechanical PR interval: a validation study. Fetal Diagn Ther 2004;19:31-4.
14. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
15. Tseng CE, Miranda E, Di Donato F, Boutjdir M, Rashbaum W, Chan EK, et al. mRNA and protein expression of SSA/Ro and SSB/La in human fetal cardiac myocytes cultured using a novel application of the Langendorff procedure. Pediatr Res 1999;45: 260-9.
16. Miranda ME, Tseng CE, Rashbaum W, Ochs RL, Casiano CA, Di Donato F, et al. Accessibility of SSA/Ro and SSB/La antigens to maternal autoantibodies in apoptotic human fetal cardiac myocytes. J Immunol 1998;161:5061-9.
17. Clancy RM, Askanase AD, Kapur RP, Chiopelas E, Azar N, Miranda-Carus ME, et al. Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block. J Immunol 2002;169:2156-63.
18. Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994; 120:544-51.
19. Silverman ED. Congenital heart block and neonatal lupus erythematosus: prevention is the goal. J Rheumatol 1993;20:1101-4.
20. Julkunen H, Kaaja R, Wallgren E, Teramo K. Isolated congenital heart block: fetal and infant outcome and familial incidence of heart block. Obstet Gynecol 1993;82:11-6.
21. Sonesson SE, Salomonsson S, Jacobsson LA, Bremme K, Wahren-Herlenius M. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum 2004;50:1253-61.
22. Rein AJ, Mevorach D, Perles Z, Shovali A, Elchalal U. Fetal first-degree heart block, or where to set the confidence limit: comment on the article by Sonesson et al [letter]. Arthritis Rheum 2005;52:366.
23. Theander E, Brucato A, Gudmundsson S, Salomonsson S, Wahren-Herlenius M, Manthorpe R. Primary Sjögren's syndrome: treatment of fetal incomplete atrioventricular block with dexamethasone. J Rheumatol 2001;28:373-6.
24. Hassan AB, Lundberg IE, Isenberg D, Wahren-Herlenius M. Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. Scand J Rheumatol 2002;31:133-9.
25. Moak JP, Barren KS, Hougen TJ, Wiles HB, Balaji S, Sreeram N, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001;37:238-42.
26. Askanase AD, Friedman DM, Copel J, Dische MR, Dubin A, Stare TJ, et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002;11:145-51.
27. Buyon JP, Rupel A, Clancy RM. Congenital heart block: do fetal factors fuel the fire from inflammation to fibrosis? [review]. Lupus 2003;12:731-4.
28. Clancy RM, Backer CB, Yin X, Kapur RP, Molad Y, Buyon JP. Cytokine polymorphisms and histologie expression in autopsy studies: contribution of TNF-α and TGF-β1 to the pathogenesis of autoimmune-associated congenital heart block. J Immunol 2003; 171:3253-61.
29. Clancy RM, Kapur RP, Molad Y, Askanase AD, Buyon JP. Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum 2004;50: 173-82.
30. Rosenthal D, Friedman DM, Buyon J, Dubin A. Validation of the Doppler PR interval in the fetus. J Am Soc Echocardiogr 2002; 15:1029-30.
31. Allen HD, Clark EB, Gutgesell HP, Driscoll DJ, editors. Moss and Adams heart disease in infants, children and adolescents. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001.